QLT announces FDA filing and review of Aczone(TM) labeling supplement for removal of blood screening requirement

QLT announces FDA filing and review of Aczone(TM) labeling supplement for removal of blood screening requirement: "VANCOUVER, July 23 /PRNewswire-FirstCall/ - QLT Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review QLT USA, Inc.'s labeling supplement (sNDA) for Aczone(TM) to request the removal of the glucose-6-phosphate dehydrogenase (G6PD) screening and blood monitoring requirements from its current label. A decision by the FDA on the label revision is expected by the end of March 2008."